Ocaliva Commercial Update
"Net U.S. Ocaliva sales for the quarter were $4.7 million.
Ocaliva was approved by the U.S. Food and Drug Administration (FDA) on May 27, 2016 for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Intercept launched Ocaliva in the United States in June 2016 and in conjunction launched Interconnect®, a comprehensive, personalized program that connects patients with dedicated Care Coordinators who help them understand their disease and provides treatment support and, for eligible patients, financial assistance options."
Any thoughts on this one, speculation has been around for a while.
Recent approval (Dec.) in Europe for Ocaliva.